PLASMOfab has passed to the second phase of its lifetime after successfully completing the Mid-project Review Meeting. The review meeting was held on October 3rd, 2017 at the EC premises in Brussels". The consortium presented the disruptive innovations and outcomes achieved already in PLASMOfab fully addressing its objectives.